News from the FDA.
- Published in:
- Patient Care (Print), 2004, v. 38, n. 8, p. 12
- Publication type:
- Article
Works matching DE "MYLAN Pharmaceuticals Inc."
Results: 19
1
2
MYLAN RECEIVES FINAL FDA APPROVALS FOR GENERIC VERSIONS OF LAMICTAL TABLETS AND LAMICTAL CD.
- Published in:
- Psychiatry (1550-5952), 2009, v. 6, n. 2, p. 14
- Publication type:
- Article
3
Reviewing St. Regis: Unresolved Issues at the Intersection of Tribal Sovereign Immunity and Patent Law.
- Published in:
- Vanderbilt Journal of Entertainment & Technology Law, 2019, v. 21, n. 4, p. 1125
- By:
- Publication type:
- Article
4
EYE SEE WHAT YOU'RE DOING: AN ANALYSIS OF ALLERGAN'S USE OF TRIBAL SOVEREIGN IMMUNITY TO EVADE IPR OF THEIR EYE PRODUCT, RESTASIS.
- Published in:
- Berkeley Technology Law Journal, 2019, v. 34, n. 4, p. 1057, doi. 10.15779/Z384M91B3S
- By:
- Publication type:
- Article
5
FDA Approves Alprazolam Extended-Release Tablets.
- Published in:
- Journal of Psychosocial Nursing & Mental Health Services, 2006, v. 44, n. 4, p. 18
- Publication type:
- Article
6
Mylan v FDA: Another court decision in favour of ‘authorised generics’.
- Published in:
- Journal of Generic Medicines, 2006, v. 4, n. 1, p. 46, doi. 10.1057/palgrave.jgm.4950043
- By:
- Publication type:
- Article
7
MYLAN V. WARNER CHILCOTT: A STUDY IN PHARMACEUTICAL PRODUCT HOPPING.
- Published in:
- Marquette Intellectual Property Law Review, 2015, v. 19, n. 2, p. 245
- By:
- Publication type:
- Article
8
From the FDA.
- Published in:
- Brown University Psychopharmacology Update, 2006, v. 17, n. 5, p. 8
- Publication type:
- Article
9
Mylan Fraud: Accounting and Disclosure Considerations.
- Published in:
- Journal of Accounting & Management (2284-9459), 2022, v. 12, n. 1, p. 121
- By:
- Publication type:
- Article
10
Clinical Trials News.
- Published in:
- Applied Clinical Trials, 2004, v. 13, n. 6, p. 18
- Publication type:
- Article
11
PATENTLY INCONSISTENT: STATE AND TRIBAL SOVEREIGN IMMUNITY IN INTER PARTES REVIEW.
- Published in:
- St. John's Law Review, 2019, v. 93, n. 1, p. 233
- By:
- Publication type:
- Article
12
From the FDA.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2006, v. 8, n. 4, p. 8
- Publication type:
- Article
13
JURY SELECTION: The Often-Overlooked Make-It-or-Break-It Phase of a Trial.
- Published in:
- Brief, 2019, v. 48, n. 2, p. 10
- By:
- Publication type:
- Article
14
MYLAN PHARMACEUTICALS, INC. V. THOMPSON.
- Published in:
- Berkeley Technology Law Journal, 2002, v. 17, n. 1, p. 155
- Publication type:
- Article
15
Birth control recall:.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2013, v. 185, n. 14, p. E667, doi. 10.1503/cmaj.109-4597
- By:
- Publication type:
- Article
16
Commentary on "The Impact of Vertical Integration on Physician Behavior and Healthcare Delivery: Evidence from Gastroenterology Practices".
- Published in:
- Management Science, 2023, v. 69, n. 12, p. 7180, doi. 10.1287/mnsc.2023.01831
- By:
- Publication type:
- Article
17
Ethics, Pricing, and the Pharmaceutical Industry. Corporate Communication Faces Drug-Cost Issues.
- Published in:
- Anglistica AION: An Interdisciplinary Journal, 2019, v. 23, n. 1, p. 175, doi. 10.19231/angl-aion.2019111
- By:
- Publication type:
- Article
18
Apomorphine-Subcutaneous – Bertek/Britannia.
- Published in:
- Drugs in R&D, 2004, v. 5, n. 4, p. 211
- By:
- Publication type:
- Article
19
BIOTECHNOLOGY PATENT LAW TOP TEN OF 2018 BROAD WINS, SOVEREIGNTY LOSES, AND PATENT DANCE.
- Published in:
- Akron Law Review, 2019, v. 52, n. 3, p. 637
- By:
- Publication type:
- Article